BofA lowered the firm’s price target on Kura Oncology (KURA) to $27 from $29 and keeps a Buy rating on the shares. The firm says that while the company’s Q2 report didn’t bring new material insights, it remains encouraged about the story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating
- Kura Oncology Advances Cancer Drug Pipeline with FDA Review
- Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating
- Kura Oncology’s Promising Clinical Developments and Financial Stability Justify Buy Rating
- Kura Oncology reports inducement grants under Nasdaq listing rule